

THE WELINK.CARE LABEL HAS BEEN AWARDED TO



FibriCheck®

ON THE 18<sup>TH</sup> OF MAY 2022

WITH THE VERY HIGH DISRUPTION SCORE OF 92 %



A handwritten signature in black ink, appearing to read 'Thierry Vermeeren', positioned above a horizontal line.

Dr. Thierry Vermeeren, CEO

The WeLink.Care label uses a composite index scoring the disruption value of a digital solution use case in the daily health practice. Our expert team has reviewed the preselected digital solution with a set of 35 points of measure, based on interviews, documents research and analysis.

## FIBRICHECK RECEIVES THE WELINK.CARE LABEL

### Introduction

FibriCheck has been awarded the prestigious WeLink.Care Label, recognizing its innovative contribution to advancing digital health solutions. This accolade underscores FibriCheck's ability to significantly enhance cardiovascular care through early detection of arrhythmias and its alignment with global healthcare needs. The label is a testament to FibriCheck's impactful design, proven utility, and capacity to transform patient outcomes across diverse healthcare ecosystems.

### About the WeLink.Care Label

The WeLink.Care Label was established as a benchmark for identifying and promoting digital health solutions that demonstrate exceptional innovation and tangible benefits to healthcare. Initially launched during the COVID-19 pandemic to address pressing global health challenges, the label has evolved into a comprehensive evaluation framework, assessing solutions across multiple healthcare domains.

This certification highlights solutions that excel in areas such as technological innovation, user experience, and economic viability. By leveraging a scientifically rigorous methodology, the WeLink.Care Label ensures that selected solutions not only meet high standards of performance but also contribute to transforming healthcare practices. Solutions bearing this label are distinguished as industry leaders capable of driving meaningful change in patient care and provider workflows.

### The Evaluation Process

The evaluation process for the WeLink.Care Label is built on a robust framework that scrutinizes solutions across five critical dimensions: Business Model, Solution Maturity, Change of Practices, and User Experience for both patients and professionals. Each dimension is further broken down into specific sub-topics to ensure a granular and thorough assessment.

Certified evaluators gather data from diverse sources, including developers, healthcare providers, and patients. Detailed interviews and stakeholder surveys form a vital part of this process, providing qualitative and quantitative insights into the solution's real-world applicability and impact. This multi-perspective approach ensures a well-rounded evaluation. The evaluation incorporates evidence from clinical studies, usage statistics, and external reviews. Solutions are benchmarked against industry standards to assess their competitiveness and alignment with healthcare needs. Key metrics such as accuracy, efficiency, and scalability are meticulously analyzed to provide a comprehensive score.

Findings from the evaluation are presented in two deliverables: the Scorecard and the Impact Study. The Scorecard provides a concise numerical overview of the evaluation results, offering immediate insights into the solution's strengths and areas for improvement. The Impact Study delves deeper, presenting detailed documentation of findings, stakeholder feedback, and actionable recommendations for optimization. This meticulous evaluation process ensures that solutions awarded the WeLink.Care Label are not only innovative but also practical and impactful, supporting their integration into diverse healthcare systems and enhancing their potential to improve global health outcomes.

# FIBRICHECK

## Introduction to the company

Founded in 2014, FibriCheck is a pioneering digital health company under Qompium NV, specializing in innovative solutions for cardiac arrhythmia detection, particularly atrial fibrillation and management. Leveraging advanced photoplethysmography (PPG) technology, the company addresses critical gaps in cardiovascular care. FibriCheck has grown from a master's thesis concept into a global leader in digital health, with a presence in Europe, the Middle East, Australia, and beyond.

FibriCheck's mission is rooted in improving patient outcomes through accessible, user-friendly technology that enables early detection and remote monitoring of **atrial fibrillation (AFib)**. With strong backing from clinical validation, global regulatory approvals, and collaborations with major stakeholders, the company continues to lead the charge in revolutionizing cardiovascular healthcare.

## The Solution

FibriCheck is a certified medical device designed to detect and monitor cardiac arrhythmias, focusing primarily on atrial fibrillation, a leading cause of strokes. The solution utilizes smartphone cameras and wearables equipped with PPG technology to capture accurate heart rhythm data through 60-second measurements. This innovative use of everyday devices allows for easy integration into patients' daily lives without requiring additional hardware.

The solution operates across a broad spectrum of use cases, from empowering individual users with peace of mind to supporting physicians in managing chronic conditions and high-risk patients. By enabling remote monitoring, FibriCheck eliminates barriers such as geographical limitations and healthcare access, making cardiac care more efficient and patient-centric.

## Features and Benefits

FibriCheck's core feature is its ability to deliver medical-grade heart rhythm analysis through consumer devices like smartphones and smartwatches. The solution provides users with instant, detailed reports that can be securely shared with healthcare providers. Its high accuracy, comparable to single-lead ECGs, ensures reliable detection of arrhythmias, even in asymptomatic or sporadic cases.

The platform benefits healthcare systems by reducing unnecessary visits and diagnostics, improving resource allocation, and enabling early intervention. For patients, FibriCheck offers convenience, affordability, and empowerment, allowing them to take charge of their heart health. These combined benefits significantly contribute to improved patient satisfaction and reduced strain on healthcare providers.


## Compliance and Future Outlook

FibriCheck complies with international medical device standards, holding certifications such as CE Class IIa and FDA approval. The company also adheres to stringent data security and privacy protocols, including ISO 27001 certifications, ensuring trust and reliability among its users. Looking ahead, FibriCheck aims to expand its global footprint, particularly in the U.S. market, and advance its offerings with innovative features like diagnostics-as-a-service. By continuing to collaborate with partners and enhance its algorithms, the company is well-positioned to remain a leader in the evolving landscape of digital cardiovascular care.

## DISRUPTION SCORE


FibriCheck demonstrates a high disruption score with widespread adoption by 2,000 doctors and reimbursement by select Belgian mutual insurance companies. Operating in Belgium, the Netherlands, and the UK, the solution leverages smartphone cameras to detect rhythm disorders, including atrial fibrillation, offering accessible and reliable screening. While CE marked and clinically validated, the lack of automatic interoperability remains a limitation. FibriCheck's innovative approach significantly enhances early detection and remote management in cardiovascular care.

### BUSINESS PERFORMANCE




|~ very good ~|

### CHANGE OF PRACTICES



|~ very significant ~|

### DISRUPTION POTENTIAL



|~ very high ~|

### SOLUTION MATURITY



|~ very high ~|

### USER EXPERIENCE



|~ very good ~|

## BUSINESS MODEL

FibriCheck's business model reflects strong growth potential, supported by a €6M funding round in 2020. While not yet profitable, the company has a solid base of 2,000 doctors using its CE-marked app, which is reimbursed by select Belgian mutual insurance companies. Operating primarily in Belgium, the UK, and the Netherlands, FibriCheck is expanding globally, with presence in Europe, Hong Kong, and the Middle East, and plans to enter the U.S. market with necessary regulatory approvals.

### BUSINESS MODEL




|~ very good ~|

### COMMERCIAL READINESS LEVEL



|~ first profits ~|

### BUSINESS PERFORMANCE



|~ very good ~|

## SOLUTION MATURITY

FibriCheck demonstrates strong solution maturity, with deployment in Belgium, the Netherlands, and the UK, ongoing expansion in the Middle East, and plans for U.S. approval. Its readiness for global deployment is supported by extensive clinical validation through numerous studies by diverse research teams. The company's development is marked by strategic collaboration with expert professionals at every stage, ensuring a robust and reliable solution for cardiac arrhythmia detection and management worldwide.

### CLINICAL TRIALS



|~ evidence-based digital practices ~|

### PREMS & PROMS



|~ sufficient ~|

### DESIGN APPROACH



|~ adequate ~|

### SOLUTION MATURITY



|~ very high ~|

### TECHNOLOGY READINESS LEVEL




|~ product deployed ~|

## CHANGE OF PRACTICES


FibriCheck transforms care practices by enabling reliable detection of rhythm disorders, particularly atrial fibrillation, using a smartphone or other PPG-enabled devices. After a 7-day monitoring period, detailed reports are sent to the cardiologist for clinical decision-making. While the solution enhances remote patient management, interoperability with medical records requires manual adaptation by each institution. Additionally, the absence of integrated interprofessional communication tools limits seamless collaboration among healthcare providers.

### PRACTICES MEASURE POINTS



| ~ 12 relevant measure points ~ |

### CHANGE OF PRACTICES



| ~ very significant ~ |

## USER EXPERIENCE : THE PROFESSIONAL AND PATIENT PERSPECTIVE

FibriCheck offers a user-friendly experience for patients and healthcare professionals, enabling seamless heart rate monitoring through PPG technology via a smartphone camera. Detailed reports are sent to cardiologists after 7 days, optimizing consultations by focusing only on patients needing direct intervention. The application integrates securely into patient files and is backed by multiple certifications. While reimbursement varies by region, the solution is affordable and accessible to many, especially older adults familiarized with smartphones during COVID confinements.




|~ very good ~|

### PROFESSIONAL EXPERIENCE



### PATIENT EXPERIENCE



|~ very good ~|

### USER EXPERIENCE



|~ very good ~|

## LINKS AND RESOURCES

<https://www.fibricheck.com/>

<https://label.welink.care/>

---

*This report is based on the information provided by the scored company, input from various stakeholders, and the application of the WeLink.Care© methodology by OZConsulting. The findings, scores, and evaluations presented are intended solely for informational purposes and do not constitute a guarantee or endorsement of the quality, effectiveness, or commercial viability of the evaluated digital health solution.*

*The conclusions are drawn from the data available at the time of the study and may not reflect subsequent changes. OZConsulting assumes no responsibility for the accuracy or completeness of the information provided by the scored company or any third parties involved. Any reliance on this report is at the reader's own risk.*

*The content of this report is protected under copyright law. No part of this report may be reproduced, distributed, or used for commercial purposes without prior written permission from OZC. The WeLink.Care© methodology and scoring system are proprietary to OZConsulting.*

---